Nextage Therapeutics (XTAE:NXTG) Total Current Assets: ₪1.69 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:NXTG Nextage Therapeutics Ltd XTAE:NXTG
8 GF Score
Price ₪0.39
GF Value ₪0.31
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Nextage Therapeutics Total Current Assets?

Nextage Therapeutics XTAE:NXTG 8 Total Current Assets is ₪1.69 Mil as of Dec. 2025. GuruFocus rates XTAE:NXTG with a GF Score™ of 8/100 and a GF Value™ of ₪0.31 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Nextage Therapeutics's total current assets for the quarter that ended in Dec. 2025 was ₪1.69 Mil.


Nextage Therapeutics  (XTAE:NXTG) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Nextage Therapeutics's Liquidation Value for the quarter that ended in Dec. 2025 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.279-32.238+0.75 * 0.901+0.5 * 0
=-31.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nextage Therapeutics Total Current Assets Related Terms


Nextage Therapeutics Total Current Assets Historical Data

* Premium members only.

The historical data trend for Nextage Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nextage Therapeutics Total Current Assets Chart

Nextage Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.16 1.42 0.89 0.58 1.69

Nextage Therapeutics Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 0.49 0.58 1.44 1.69
XTAE:NXTG
8GF Score
Nextage Therapeutics Ltd XTAE:NXTG
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nextage Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Nextage Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Nextage Therapeutics's Total Current Assets for the quarter that ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of ₪1.69 Mil mean?
Nextage Therapeutics (XTAE:NXTG) has a Total Current Assets of ₪1.69 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Nextage Therapeutics and its competitors.
Is Nextage Therapeutics' Total Current Assets too high?
Nextage Therapeutics' current Total Current Assets is ₪1.69 Mil. Overall, Nextage Therapeutics has a GF Score™ of 8/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nextage Therapeutics' Total Current Assets compare to ZTS and UTHR?
Nextage Therapeutics' Total Current Assets of ₪1.69 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Drug Manufacturers company?
A good Total Current Assets depends on the Drug Manufacturers industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Nextage Therapeutics and its competitors. Nextage Therapeutics's current Total Current Assets is ₪1.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nextage Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nextage Therapeutics (XTAE:NXTG) is currently considered Modestly Overvalued. The stock's GF Value™ is ₪0.31, compared to a current price of ₪0.39 — trading 25.8% above its estimated fair value. The current Total Current Assets is ₪1.69 Mil. Nextage Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Nextage Therapeutics (XTAE:NXTG), the current Total Current Assets is ₪1.69 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nextage Therapeutics (XTAE:NXTG) Overvalued in 2026?

Based on GuruFocus' analysis, Nextage Therapeutics stock appears to be overvalued. The current stock price of ₪0.39 is trading 25.8% above its estimated GF Value™ of ₪0.31. GuruFocus considers Nextage Therapeutics to be Modestly Overvalued.

Key valuation signals for XTAE:NXTG:

  • Total Current Assets: ₪1.69 Mil
  • GF Value™: ₪0.31 vs. price of ₪0.39 (25.8% above fair value)
  • GF Score™: 8/100 with 4 warning signs

No single metric tells the full story. See the XTAE:NXTG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nextage Therapeutics Business Description

Address Bio-Light, Kiryat Atidim 7, Entrance 1, 2rd Floor, Tel Aviv, ISR, 61581
Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.
8GF Score

Get the complete analysis for XTAE:NXTG

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪0.39
Price
₪0.31
GF Value